CO2022001195A2 - Anticuerpos dirigidos contra dll3 y usos de los mismos - Google Patents
Anticuerpos dirigidos contra dll3 y usos de los mismosInfo
- Publication number
- CO2022001195A2 CO2022001195A2 CONC2022/0001195A CO2022001195A CO2022001195A2 CO 2022001195 A2 CO2022001195 A2 CO 2022001195A2 CO 2022001195 A CO2022001195 A CO 2022001195A CO 2022001195 A2 CO2022001195 A2 CO 2022001195A2
- Authority
- CO
- Colombia
- Prior art keywords
- dll3
- directed against
- antibodies directed
- antibodies
- against dll3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962872915P | 2019-07-11 | 2019-07-11 | |
| PCT/US2020/041282 WO2021007371A1 (en) | 2019-07-11 | 2020-07-08 | Dll3-targeting antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022001195A2 true CO2022001195A2 (es) | 2022-03-08 |
Family
ID=74115317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0001195A CO2022001195A2 (es) | 2019-07-11 | 2022-02-04 | Anticuerpos dirigidos contra dll3 y usos de los mismos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12441789B2 (enExample) |
| EP (1) | EP3997127A4 (enExample) |
| JP (2) | JP7661299B2 (enExample) |
| KR (1) | KR20220034167A (enExample) |
| CN (3) | CN119080930A (enExample) |
| AU (1) | AU2020310894A1 (enExample) |
| BR (1) | BR112022000216A2 (enExample) |
| CA (1) | CA3146566A1 (enExample) |
| CO (1) | CO2022001195A2 (enExample) |
| IL (1) | IL289585A (enExample) |
| MX (1) | MX2022000325A (enExample) |
| PH (1) | PH12022550056A1 (enExample) |
| WO (1) | WO2021007371A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2718257T3 (enExample) * | 2014-05-30 | 2018-04-14 | ||
| BR112022000216A2 (pt) * | 2019-07-11 | 2022-05-17 | Memorial Sloan Kettering Cancer Center | Anticorpos direcionados a dll3 e usos dos mesmos |
| WO2022153195A1 (en) * | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
| WO2022153194A1 (en) * | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
| WO2022237647A1 (zh) * | 2021-05-08 | 2022-11-17 | 上海齐鲁制药研究中心有限公司 | 针对dll3的结合分子及其应用 |
| WO2023034557A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof |
| WO2023034555A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting dll3 and uses thereof |
| EP4396224A4 (en) * | 2021-09-02 | 2025-11-12 | Memorial Sloan Kettering Cancer Center | Anti-DLL3 Antibodies and Their Uses |
| EP4454662A4 (en) * | 2021-12-23 | 2025-04-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ANTI-DLL3 ANTIBODY AND PHARMACEUTICAL USE THEREOF, AND ANTIBODY-DRUG CONJUGATE CONTAINING AN ANTI-DLL3 ANTIBODY |
| KR20240149438A (ko) | 2022-02-27 | 2024-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | Cd277 및 종양-항원에 대한 이중특이적 항체 |
| CN116003628A (zh) * | 2022-08-15 | 2023-04-25 | 南京博安生物技术有限公司 | 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用 |
| WO2025184421A1 (en) * | 2024-02-28 | 2025-09-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7288253B2 (en) | 2003-08-08 | 2007-10-30 | Amgen Fremont, Inc. | Antibodies directed to parathyroid hormone (PTH) and uses thereof |
| AU2007325872B2 (en) * | 2006-11-08 | 2012-12-13 | Macrogenics West, Inc. | TES7 and antibodies that bind thereto |
| EP3907242A1 (en) | 2010-01-29 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-dll3 antibody |
| WO2012013813A1 (en) | 2010-07-30 | 2012-02-02 | Gianluca Moroncini | Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof |
| AU2013215254B2 (en) * | 2012-01-31 | 2017-08-31 | Regeneron Pharmaceuticals, Inc. | Anti-ASIC1 antibodies and uses thereof |
| RU2014138474A (ru) * | 2012-02-24 | 2016-04-10 | СтемСентРкс, Инк. | Новые модуляторы и способы применения |
| WO2015127407A1 (en) * | 2014-02-21 | 2015-08-27 | Stemcentrx, Inc. | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| UY36245A (es) | 2014-07-31 | 2016-01-29 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| EP3221356B1 (en) | 2014-11-20 | 2020-09-02 | F.Hoffmann-La Roche Ag | T cell activating bispecific antigen binding molecules against folr1 and cd3 |
| BR112022000216A2 (pt) * | 2019-07-11 | 2022-05-17 | Memorial Sloan Kettering Cancer Center | Anticorpos direcionados a dll3 e usos dos mesmos |
-
2020
- 2020-07-08 BR BR112022000216A patent/BR112022000216A2/pt unknown
- 2020-07-08 JP JP2022501134A patent/JP7661299B2/ja active Active
- 2020-07-08 AU AU2020310894A patent/AU2020310894A1/en active Pending
- 2020-07-08 CA CA3146566A patent/CA3146566A1/en active Pending
- 2020-07-08 EP EP20836805.0A patent/EP3997127A4/en active Pending
- 2020-07-08 CN CN202411174923.9A patent/CN119080930A/zh active Pending
- 2020-07-08 KR KR1020227004114A patent/KR20220034167A/ko active Pending
- 2020-07-08 US US17/622,404 patent/US12441789B2/en active Active
- 2020-07-08 PH PH1/2022/550056A patent/PH12022550056A1/en unknown
- 2020-07-08 MX MX2022000325A patent/MX2022000325A/es unknown
- 2020-07-08 WO PCT/US2020/041282 patent/WO2021007371A1/en not_active Ceased
- 2020-07-08 CN CN202080062231.9A patent/CN114341182B/zh active Active
- 2020-07-08 CN CN202411174926.2A patent/CN118955717A/zh active Pending
-
2022
- 2022-01-03 IL IL289585A patent/IL289585A/en unknown
- 2022-02-04 CO CONC2022/0001195A patent/CO2022001195A2/es unknown
-
2025
- 2025-04-02 JP JP2025061352A patent/JP2025156278A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020310894A1 (en) | 2022-02-03 |
| EP3997127A1 (en) | 2022-05-18 |
| JP2022540611A (ja) | 2022-09-16 |
| KR20220034167A (ko) | 2022-03-17 |
| JP7661299B2 (ja) | 2025-04-14 |
| WO2021007371A1 (en) | 2021-01-14 |
| BR112022000216A2 (pt) | 2022-05-17 |
| CN114341182B (zh) | 2024-09-10 |
| JP2025156278A (ja) | 2025-10-14 |
| US20220348648A1 (en) | 2022-11-03 |
| CA3146566A1 (en) | 2021-01-14 |
| EP3997127A4 (en) | 2023-08-23 |
| CN119080930A (zh) | 2024-12-06 |
| IL289585A (en) | 2022-03-01 |
| PH12022550056A1 (en) | 2023-04-12 |
| CN118955717A (zh) | 2024-11-15 |
| US12441789B2 (en) | 2025-10-14 |
| MX2022000325A (es) | 2022-03-25 |
| CN114341182A (zh) | 2022-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022000325A (es) | Anticuerpos dirigidos contra dll3 y usos de los mismos. | |
| MX2021009975A (es) | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer. | |
| CL2019002855A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno. | |
| CL2023000895A1 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
| CL2020002446A1 (es) | Anticuerpos contra mica y/o micb y sus usos | |
| WO2018170338A3 (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| MX2022015901A (es) | Proteinas de union biespecificas y usos de las mismas. | |
| ECSP21010450A (es) | Anticuerpos antisortilina y métodos para su uso | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| SA519402358B1 (ar) | Ccr7 مترافقات عقار جسم مضاد لـ | |
| BR112022006620A2 (pt) | Anticorpos contra o receptor de poliovírus (pvr) e seus usos | |
| BR112019000431A2 (pt) | anticorpos contra tim3 e usos dos mesmos | |
| EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
| MX2019007554A (es) | Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso. | |
| WO2018031490A3 (en) | Anti-ox40 binding proteins | |
| EA036814B9 (ru) | Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение | |
| BR112014018481A2 (pt) | anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso | |
| WO2018069871A3 (en) | Anti-kras binding proteins | |
| CO2018012497A2 (es) | Anticuerpos de interferón beta y usos de los mismos | |
| ZA202008095B (en) | Humanized antibodies against psma | |
| EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
| MX2023011788A (es) | Anticuerpos contra ilt4, anticuerpo biespecifico anti-ilt4/pd-l1 y usos de los mismos. | |
| CO2023000557A2 (es) | Anticuerpos y métodos para tratar enfermedades asociadas a claudina | |
| BR112019007147A2 (pt) | anticorpos anti-o1 e usos dos mesmos | |
| CO2018001985A2 (es) | Polipéptidos mrka, anticuerpos y usos de los mismos |